Sensei Biotherapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Sensei Biotherapeutics (SNSE) with a Buy rating and $5 price target Sensei is developing conditionally active antibodies designed to selectively function the tumor microenvironments, the analyst tells investors in a research note. The firm says Sensei has the potential to deliver a novel immune checkpoint inhibitor antibody for solid tumors.